REGENXBIO EBITDA 2011-2026 | RGNX

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA REGENXBIO

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-251 M	-250 M	170 M	-111 M	-142 M	92.1 M	-73.2 M	-64.8 M	-23 M	-3.65 M	-4.76 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
170 M	-251 M	-60.1 M

Quarterly EBITDA REGENXBIO

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-59.7 M	-	-	-	-62 M	-	-62.3 M	-62.5 M	-68.9 M	-	-50.4 M	-52.2 M	-42.1 M	-	20.3 M	-37.7 M	-35.7 M	-	-30.7 M	-33.5 M	-34.3 M	-	-20.1 M	8.08 M	103 M	-	-19.3 M	-13.8 M	-22.4 M	-	-18.4 M	-14.8 M	-11.2 M	-	-7.3 M	-6.28 M	-3.99 M	-	-1.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
103 M	-68.9 M	-23.7 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	-150 M	$ 2.13	-12.55 %	$ 219 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
BioCardia BCDA	-11.6 M	$ 1.37	6.2 %	$ 29 M	USA
Black Diamond Therapeutics BDTX	-78.4 M	$ 2.4	-2.83 %	$ 132 M	USA
BioLineRx Ltd. BLRX	-24.8 M	$ 2.8	-1.06 %	$ 908 M	Israel
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
BioXcel Therapeutics BTAI	-66.9 M	$ 1.64	-1.8 %	$ 4.16 M	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
BeyondSpring BYSI	-66.2 M	$ 1.44	6.3 %	$ 58.1 M	USA
Cabaletta Bio CABA	-73.2 M	$ 3.34	0.6 %	$ 3.9 M	USA
AbCellera Biologics ABCL	-199 M	$ 3.7	2.49 %	$ 1.11 B	Canada
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Codexis CDXS	-53.6 M	$ 1.05	3.47 %	$ 77.1 M	USA
Cerus Corporation CERS	-12.4 M	$ 2.6	1.56 %	$ 480 M	USA
Certara CERT	96.2 M	$ 7.17	1.27 %	$ 1.15 B	USA
Cullinan Management CGEM	-197 M	$ 15.91	2.65 %	$ 931 M	USA
Compugen Ltd. CGEN	-34.6 M	$ 2.28	25.97 %	$ 204 M	Israel
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Coherus BioSciences CHRS	-200 M	$ 1.66	-0.9 %	$ 156 M	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Cellectis S.A. CLLS	-131 M	$ 3.88	-	$ 116 M	France
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	-65 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
CNS Pharmaceuticals CNSP	-14.9 M	$ 3.1	-0.44 %	$ 1.18 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Cocrystal Pharma COCP	-17.8 M	$ 1.02	-0.97 %	$ 10.4 M	USA
Aptose Biosciences APTO	32 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Collegium Pharmaceutical COLL	64.9 M	$ 42.0	0.79 %	$ 1.33 B	USA
Corcept Therapeutics Incorporated CORT	45.9 M	$ 35.61	-0.25 %	$ 3.7 B	USA
Athira Pharma ATHA	-99.9 M	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	-29.5 M	-	17.91 %	$ 11.1 M	USA